Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14


The emerging role of deubiquitinating enzymes in genomic integrity, diseases, and therapeutics.

He M, Zhou Z, Shah AA, Zou H, Tao J, Chen Q, Wan Y.

Cell Biosci. 2016 Dec 20;6:62. doi: 10.1186/s13578-016-0127-1. eCollection 2016. Review.


SkIndia Quiz 27: Rhinophyma and numerous facial papule and nodules in a 39-year-old woman.

Mahajan VK, Sharma AL, Chauhan PS, Mehta KS, Sharma S.

Indian Dermatol Online J. 2016 Jul-Aug;7(4):350-2. doi: 10.4103/2229-5178.182404. No abstract available.


Epidermal CYLD inactivation sensitizes mice to the development of sebaceous and basaloid skin tumors.

Jin YJ, Wang S, Cho J, Selim MA, Wright T, Mosialos G, Zhang JY.

JCI Insight. 2016 Jul 21;1(11). pii: e86548.


Twelve Years' Observation of Multiple Familial Trichoepithelioma with Squamous Carcinoma.

Ma H, Feng S, Pei W, Jin F.

Indian J Dermatol. 2016 May-Jun;61(3):348. doi: 10.4103/0019-5154.182464.


Brooke-Spiegler Syndrome and Phenotypic Variants: An Update.

Kazakov DV.

Head Neck Pathol. 2016 Jun;10(2):125-30. doi: 10.1007/s12105-016-0705-x. Epub 2016 Mar 14. Review.


Hematopoietic stem cell quiescence and function are controlled by the CYLD-TRAF2-p38MAPK pathway.

Tesio M, Tang Y, Müdder K, Saini M, von Paleske L, Macintyre E, Pasparakis M, Waisman A, Trumpp A.

J Exp Med. 2015 Apr 6;212(4):525-38. doi: 10.1084/jem.20141438. Epub 2015 Mar 30.


Brooke-spiegler syndrome: a rare entity.

Rathi M, Awasthi S, Budania SK, Ahmad F, Dutta S, Kumar A.

Case Rep Pathol. 2014;2014:231895. doi: 10.1155/2014/231895. Epub 2014 Jan 23.


The role of the c-Jun N-terminal Kinase signaling pathway in skin cancer.

Zhang JY, Selim MA.

Am J Cancer Res. 2012;2(6):691-8. Epub 2012 Nov 20.


Tumor Suppressor Function of CYLD in Nonmelanoma Skin Cancer.

Masoumi KC, Shaw-Hallgren G, Massoumi R.

J Skin Cancer. 2011;2011:614097. doi: 10.1155/2011/614097. Epub 2011 Dec 17.


Cylindroma transforming into basal cell carcinoma in a patient with Brooke-Spiegler syndrome.

Sicinska J, Rakowska A, Czuwara-Ladykowska J, Mroz A, Lipinski M, Nasierowska-Guttmejer A, Sikorska J, Sklinda K, Slowinska M, Kowalska-Oledzka E, Walecka I, Walecki J, Rudnicka L.

J Dermatol Case Rep. 2007 Dec 29;1(1):4-9. doi: 10.3315/jdcr.2007.1.1002.


Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours.

Rajan N, Elliott R, Clewes O, Mackay A, Reis-Filho JS, Burn J, Langtry J, Sieber-Blum M, Lord CJ, Ashworth A.

Oncogene. 2011 Oct 13;30(41):4243-60. doi: 10.1038/onc.2011.133. Epub 2011 May 9.


USP17 regulates Ras activation and cell proliferation by blocking RCE1 activity.

Burrows JF, Kelvin AA, McFarlane C, Burden RE, McGrattan MJ, De la Vega M, Govender U, Quinn DJ, Dib K, Gadina M, Scott CJ, Johnston JA.

J Biol Chem. 2009 Apr 3;284(14):9587-95. doi: 10.1074/jbc.M807216200. Epub 2009 Feb 2.


Deubiquitylating enzymes and disease.

Singhal S, Taylor MC, Baker RT.

BMC Biochem. 2008 Oct 21;9 Suppl 1:S3. doi: 10.1186/1471-2091-9-S1-S3. Review.

Supplemental Content

Support Center